Pembrolizumab / vibostolimab

Extended indication	in combination with etoposide and platinum chemotherapy, is indicated for the first line treatment of adults with extensive stage small cell lung cancer (ES SCLC)
Therapeutic value	No estimate possible yet
Registration phase	Clinical trials

Product

Active substance	Pembrolizumab / vibostolimab
Domain	Oncology
Reason of inclusion	New medicine (specialité)
Main indication	Lung cancer
Extended indication	in combination with etoposide and platinum chemotherapy, is indicated for the first line treatment of adults with extensive stage small cell lung cancer (ES SCLC)
Manufacturer	MSD
Portfolio holder	MSD
Route of administration	Intravenous
Budgetting framework	Intermural (MSZ)

Registration route	Centralised (EMA)
Type of trajectory	Normal trajectory
Particularity	New therapeutical formulation
ATMP	No
Submission date	January 2025
Expected Registration	2025
Orphan drug	No
Registration phase	Clinical trials

Current treatment options	none, atezolizumab is not reimbursed in NL
Therapeutic value	No estimate possible yet
Substantiation	De studie is gestopt vanwege bijwerkingen en resultaten.
Duration of treatment	Maximal 2 year / years
Frequency of administration	1 times every 3 weeks
Dosage per administration	200 mg / 200mg
References	NCT05224141

Patient volume	< 1,160 Market share is generally not included unless otherwise stated.
References	1: NKR2021.
Additional remarks	In 2021 waren er in totaal 1.646 patiënten met kleincellig longcarcinoom. Hiervan betrof het in 1.160 patiënten met een stadium 4 carcinoom.

Patient volume

< 1,160

Market share is generally not included unless otherwise stated.

References

1: NKR2021.

Additional remarks

In 2021 waren er in totaal 1.646 patiënten met kleincellig longcarcinoom. Hiervan betrof het in 1.160 patiënten met een stadium 4 carcinoom.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.